Primary hyperammonaemia: Current diagnostic and therapeutic strategies

1Häberle J, Rubio V. Disorders of the urea cycle and related enzymes. In: Saudubray J-M, Baumgartner MR, Walter JH, editors. Inborn metabolic diseases: diagnosis and treatment. 6th ed. Berlin, Heidelberg: Springer; 2016. XXXI, pp. 295–308, 658 p. ISBN 978-3-662-49769-2. Häberle J Rubio V Disorders of the urea cycle and related enzymes Saudubray J-M Baumgartner MR Walter JH Inborn metabolic diseases: diagnosis and treatment. 6th ed Berlin, Heidelberg Springer 2016 295 308 65810.1007/978-3-662-49771-5_19Search in Google Scholar

2Häussinger D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem J. 1990;267(2):281–90. doi: 10.1042/bj2670281 Häussinger D Nitrogen metabolism in liver: structural and functional organization and physiological relevance Biochem J 1990 2672281 90 10.1042/bj267028111312842185740Open DOISearch in Google Scholar

3Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML. Urea cycle disorders overview. 2003 Apr 29 [updated 2017 Jun 22]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, Genetic counseling, editors. GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993–2020. ISSN 2372-0697. Ah Mew N Simpson KL Gropman AL Lanpher BC Chapman KA Summar ML. Urea cycle disorders overview. 2003 Apr 29 [updated 2017 Jun 22] Adam MP Ardinger HH Pagon RA Wallace SE Bean LJH Stephens K Amemiya A Genetic counseling, editors. GeneReviews® [Internet] Seattle, WA University of Washington; 1993–2020 ISSN 2372-0697Search in Google Scholar

4Häberle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192–230. doi: 10.1002/jimd.12100 Häberle J Burlina A Chakrapani A Dixon M Karall D Lindner M et al Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision J Inherit Metab Dis 2019 4261192 230 10.1002/jimd.1210030982989Open DOISearch in Google Scholar

5Tuchman M. The clinical, biochemical, and molecular spectrum of ornithine transcarbamylase deficiency. J Lab Clin Med. 1992;120(6):836–50. Tuchman M The clinical, biochemical, and molecular spectrum of ornithine transcarbamylase deficiency J Lab Clin Med 1992 1206836 50Search in Google Scholar

6Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Allewell NM. The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. J Inherit Metab Dis. 1998;21(Suppl 1):40–58. doi: 10.1023/a:1005353407220 Tuchman M Morizono H Rajagopal BS Plante RJ Allewell NM The biochemical and molecular spectrum of ornithine transcarbamylase deficiency J Inherit Metab Dis 1998 21Suppl 140 58 10.1023/a:1005353407220Open DOISearch in Google Scholar

7Häberle J. Clinical and biochemical aspects of primary and secondary hyperammonemic disorders. Arch Biochem Biophys. 2013;536(2):101–8. doi: 10.1016/j.abb.2013.04.009 Häberle J Clinical and biochemical aspects of primary and secondary hyperammonemic disorders Arch Biochem Biophys 2013 5362101 8 10.1016/j.abb.2013.04.00923628343Open DOISearch in Google Scholar

8Summar ML, Koelker S, Freedenberg D, Le Mons C, Haberle J, Lee HS, et al.; European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD). Electronic address: http://www.e-imd.org/en/index.phtml; Members of the Urea Cycle Disorders Consortium (UCDC). Electronic address: http://rarediseasesnetwork.epi.usf.edu/ucdc/. The incidence of urea cycle disorders. Mol Genet Metab. 2013;110(1–2):179–80. doi: 10.1016/j.ymgme.2013.07.008 Summar ML Koelker S Freedenberg D Le Mons C Haberle J Lee HS et al European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD) Electronic address http://www.e-imd.org/en/index.phtml Members of the Urea Cycle Disorders Consortium (UCDC). Electronic address http://rarediseasesnetwork.epi.usf.edu/ucdc/ The incidence of urea cycle disorders. Mol Genet Metab 2013 1101–2179 80 10.1016/j.ymgme.2013.07.008436441323972786Open DOISearch in Google Scholar

9Sancho-Vaello E, Marco-Marín C, Gougeard N, Fernández-Murga L, Rüfenacht V, Mustedanagic M, et al. Understanding N-acetyl-L-glutamate synthase deficiency: mutational spectrum, impact of clinical mutations on enzyme functionality, and structural considerations. Hum Mutat. 2016;37(7):679–94. doi: 10.1002/humu.22995 Sancho-Vaello E Marco-Marín C Gougeard N Fernández-Murga L Rüfenacht V Mustedanagic M et al Understanding N-acetyl-L-glutamate synthase deficiency: mutational spectrum, impact of clinical mutations on enzyme functionality, and structural considerations Hum Mutat 2016 377679 94 10.1002/humu.2299527037498Open DOISearch in Google Scholar

10Dimmock D, Maranda B, Dionisi-Vici C, Wang J, Kleppe S, Fiermonte G, et al. Citrin deficiency, a perplexing global disorder. Mol Genet Metab. 2009;96(1):44–9. doi: 10.1016/j. ymgme.2008.10.007 Dimmock D Maranda B Dionisi-Vici C Wang J Kleppe S Fiermonte G et al Citrin deficiency, a perplexing global disorder Mol Genet Metab 2009 96144 9 10.1016/j.ymgme.2008.10.00719036621Open DOISearch in Google Scholar

11Saheki T, Inoue K, Tushima A, Mutoh K, Kobayashi K. Citrin deficiency and current treatment concepts. Mol Genet Metab. 2010;100(Suppl 1):S59–64. doi: 10.1016/j.ymgme.2010.02.014 Saheki T Inoue K Tushima A Mutoh K Kobayashi K Citrin deficiency and current treatment concepts Mol Genet Metab 2010 100Suppl 1S59 64 10.1016/j.ymgme.2010.02.01420233664Open DOISearch in Google Scholar

12Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H. Genotype-phenotype correlations in ornithine transcarbamylase deficiency: a mutation update. J Genet Genomics. 2015;42(5): 181–94. doi: 10.1016/j.jgg.2015.04.003 Caldovic L Abdikarim I Narain S Tuchman M Morizono H Genotype-phenotype correlations in ornithine transcarbamylase deficiency: a mutation update J Genet Genomics 2015 425 181 94 10.1016/j.jgg.2015.04.003456514026059767Open DOISearch in Google Scholar

13Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. J Inherit Metab Dis. 2007;30(6):865–79. doi: 10.1007/s10545-007-0709-5 Gropman AL Summar M Leonard JV Neurological implications of urea cycle disorders J Inherit Metab Dis 2007 306865 79 10.1007/s10545-007-0709-5375869318038189Open DOISearch in Google Scholar

14Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab. 2010;100(Suppl 1):S3–12. doi: 10.1016/j.ymgme.2010.02.010 Braissant O Current concepts in the pathogenesis of urea cycle disorders Mol Genet Metab 2010 100Suppl 1S3 12 10.1016/j.ymgme.2010.02.01020227314Open DOISearch in Google Scholar

15Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the brain. J Inherit Metab Dis. 2013;36(4):595–612. doi: 10.1007/s10545-012-9546-2 Braissant O McLin VA Cudalbu C Ammonia toxicity to the brain J Inherit Metab Dis 2013 364595 612 10.1007/s10545-012-9546-223109059Open DOISearch in Google Scholar

16Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol. 2002;7(1):27–35. doi: 10.1053/siny.2001.0085 Leonard JV Morris AA Urea cycle disorders Semin Neonatol 2002 7127 35 10.1053/siny.2001.008512069536Open DOISearch in Google Scholar

17Nassogne MC, Héron B, Touati G, Rabier D, Saudubray JM. Urea cycle defects: management and outcome. J Inherit Metab Dis. 2005;28(3):407–14. doi: 10.1007/s10545-005-0303-7 Nassogne MC Héron B Touati G Rabier D Saudubray JM Urea cycle defects: management and outcome J Inherit Metab Dis 2005 283407 14 10.1007/s10545-005-0303-715868473Open DOISearch in Google Scholar

18Serrano M, Martins C, Pérez-Dueñas B, Gómez-López L, Murgui E, Fons C, et al. Neuropsychiatric manifestations in late-onset urea cycle disorder patients. J Child Neurol. 2010;25(3):352–8. doi: 10.1177/0883073809340696 Serrano M Martins C Pérez-Dueñas B Gómez-López L Murgui E Fons C et al Neuropsychiatric manifestations in late-onset urea cycle disorder patients J Child Neurol 2010 253352 8 10.1177/088307380934069619684305Open DOISearch in Google Scholar

19Fantur M, Karall D, Scholl-Buergi S, Häberle J, Rauchenzauner M, Fruehwirth M. Recurrent somnolence in a 17-month-old infant: late-onset ornithine transcarbamylase (OTC) deficiency due to the novel hemizygous mutation c.535C > T (p.Leu179Phe). Eur J Paediatr Neurol. 2013;17(1):112–5. doi: 10.1016/j. ejpn.2012.05.007 Fantur M Karall D Scholl-Buergi S Häberle J Rauchenzauner M Fruehwirth M Recurrent somnolence in a 17-month-old infant: late-onset ornithine transcarbamylase (OTC) deficiency due to the novel hemizygous mutation c.535C > T (p.Leu179Phe) Eur J Paediatr Neurol 2013 171112 5 10.1016/j.ejpn.2012.05.00722727265Open DOISearch in Google Scholar

20Ihara K, Yoshino M, Hoshina T, Harada N, Kojima-Ishii K, Makimura M, et al. Coagulopathy in patients with late-onset ornithine transcarbamylase deficiency in remission state: a previously unrecognized complication. Pediatrics. 2013;131(1):e327–30. doi: 10.1542/peds.2012-0030 Ihara K Yoshino M Hoshina T Harada N Kojima-Ishii K Makimura M et al Coagulopathy in patients with late-onset ornithine transcarbamylase deficiency in remission state: a previously unrecognized complication Pediatrics 2013 1311e327 30 10.1542/peds.2012-003023209112Open DOISearch in Google Scholar

21Gropman AL, Batshaw ML. Cognitive outcome in urea cycle disorders. Mol Genet Metab. 2004;81(Suppl 1):S58–62. doi: 10.1016/j.ymgme.2003.11.016 Gropman AL Batshaw ML Cognitive outcome in urea cycle disorders Mol Genet Metab 2004 81Suppl 1S58 62 10.1016/j.ymgme.2003.11.01615050975Open DOISearch in Google Scholar

22Gropman AL, Prust M, Breeden A, Fricke S, VanMeter J. Urea cycle defects and hyperammonemia: effects on functional imaging. Metab Brain Dis. 2013;28(2):269–75. doi: 10.1007/s11011-012-9348-0 Gropman AL Prust M Breeden A Fricke S VanMeter J Urea cycle defects and hyperammonemia: effects on functional imaging Metab Brain Dis 2013 282269 75 10.1007/s11011-012-9348-0359435623149878Open DOISearch in Google Scholar

23Hediger N, Landolt MA, Diez-Fernandez C, Huemer M, Häberle J. The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders. J Inherit Metab Dis. 2018;41(4):689–98. doi: 10.1007/s10545-018-0157-4 Hediger N Landolt MA Diez-Fernandez C Huemer M Häberle J The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders J Inherit Metab Dis 2018 414689 98 10.1007/s10545-018-0157-429520739Open DOISearch in Google Scholar

24Vergano SA, Crossette JM, Cusick FC, Desai BR, Deardorff MA, Sondheimer N. Improving surveillance for hyperammonemia in the newborn. Mol Genet Metab. 2013;110(1–2):102–5. doi: 10.1016/j.ymgme.2013.05.005 Vergano SA Crossette JM Cusick FC Desai BR Deardorff MA Sondheimer N Improving surveillance for hyperammonemia in the newborn Mol Genet Metab 2013 1101–2102 5 10.1016/j.ymgme.2013.05.005375501623746553Open DOISearch in Google Scholar

25Häberle J, Rubio V. Hyperammonemias and related disorders. pp. 47–62. doi: 10.1007/978-3-642-40337-8_4. In: Blau N, Duran M, Gibsin KM, Dionisi-Vici C, editors. Physician’s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. Berlin, Heidelberg: Springer; 2014; XLV, 867 p. ISBN 978-3-642-40336-1. eBook ISBN 978-3-642-40337-8. doi: 10.1007/978-3-642-40337-8. Häberle J Rubio V Hyperammonemias and related disorders 47 62 10.1007/978-3-642-40337-8_4 In: Blau N, Duran M, Gibsin KM, Dionisi-Vici C, editors. Physician’s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. Berlin, Heidelberg: Springer; 2014; XLV, 867 p. ISBN 978-3-642-40336-1. eBook ISBN 978-3-642-40337-8 10.1007/978-3-642-40337-8Open DOISearch in Google Scholar

26Häberle J, Koch HG. Genetic approach to prenatal diagnosis in urea cycle defects. Prenat Diagn. 2004;24(5):378–83. doi: 10.1002/pd.884 Häberle J Koch HG Genetic approach to prenatal diagnosis in urea cycle defects Prenat Diagn 2004 245378 83 10.1002/pd.88415164414Open DOISearch in Google Scholar

27Gautschi M, Eggimann S, Nuofer J-M. Current role of enzyme analysis for urea cycle disorders. J Pediatr Biochem. 2014;4(1):23–32. doi: 10.3233/JPB-140103 Gautschi M Eggimann S Nuofer J-M Current role of enzyme analysis for urea cycle disorders J Pediatr Biochem 2014 4123 32 10.3233/JPB-140103Open DOISearch in Google Scholar

28Yudkof M, Ah Mew N, Daikhin Y, Horyn O, Nissim I, Nissim I, et al. Measuring in vivo ureagenesis with stable isotopes. Mol Genet Metab. 2010;100(Suppl 1):S37–41. doi: 10.1016/j. ymgme.2010.02.017 Yudkof M Ah Mew N Daikhin Y Horyn O Nissim I Nissim I et al Measuring in vivo ureagenesis with stable isotopes Mol Genet Metab 2010 100Suppl 1S37 41 10.1016/j.ymgme.2010.02.017285879320338795Open DOISearch in Google Scholar

29Yudkof M, Daikhin Y, Ye X, Wilson JM, Batshaw ML. In vivo measurement of ureagenesis with stable isotopes. J Inherit Metab Dis. 1998;21(Suppl 1):21–9. doi: 10.1023/a:1005345205403 Yudkof M Daikhin Y Ye X Wilson JM Batshaw ML In vivo measurement of ureagenesis with stable isotopes J Inherit Metab Dis 1998 21Suppl 121 9 10.1023/a:1005345205403Open DOISearch in Google Scholar

30Mew NA, Yudkoff M, Tuchman M. Stable isotopes in the diagnosis and treatment of inherited hyperammonemia. J Pediatr Biochem. 2014;4(1):57–63. doi: 10.3233/JPB-140106 Mew NA Yudkoff M Tuchman M Stable isotopes in the diagnosis and treatment of inherited hyperammonemia J Pediatr Biochem 2014 4157 63 10.3233/JPB-140106395200224634704Open DOISearch in Google Scholar

31Allegri G, Deplazes S, Grisch-Chan HM, Mathis D, Fingerhut R, Häberle J, et al. A simple dried blood spot-method for in vivo measurement of ureagenesis by gas chromatography-mass spectrometry using stable isotopes. Clin Chim Acta. 2017;464:236–43. doi: 10.1016/j.cca.2016.11.038 Allegri G Deplazes S Grisch-Chan HM Mathis D Fingerhut R Häberle J et al A simple dried blood spot-method for in vivo measurement of ureagenesis by gas chromatography-mass spectrometry using stable isotopes Clin Chim Acta 2017 464236 43 10.1016/j.cca.2016.11.03827923571Open DOISearch in Google Scholar

32Ah Mew N, McCarter R, Daikhin Y, Lichter-Konecki U, Nissim I, Yudkof M, et al. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate. J Pediatr. 2014;165(2):401–3.e3. doi: 10.1016/j. jpeds.2014.04.012 Ah Mew N McCarter R Daikhin Y Lichter-Konecki U Nissim I Yudkof M et al Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate J Pediatr 2014 1652401 3 10.1016/j.jpeds.2014.04.012411199324880889Open DOISearch in Google Scholar

33Häberle J. Clinical practice: the management of hyperammonemia. Eur J Pediatr. 2011;170(1):21–34. doi: 10.1007/s00431-010-1369-2 Häberle J Clinical practice: the management of hyperammonemia Eur J Pediatr 2011 170121 34 10.1007/s00431-010-1369-221165747Open DOISearch in Google Scholar

34Picca S, Bartuli A, Dionisi-Vici C. Medical management and dialysis therapy for the infant with an inborn error of metabolism. Semin Nephrol. 2008;28(5):477–80. doi: 10.1016/j. semnephrol.2008.05.007 Picca S Bartuli A Dionisi-Vici C Medical management and dialysis therapy for the infant with an inborn error of metabolism Semin Nephrol 2008 285477 80 10.1016/j.semnephrol.2008.05.00718790367Open DOISearch in Google Scholar

35Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi M, et al. Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol. 2001;16(11):862–7. doi: 10.1007/s004670100702 Picca S Dionisi-Vici C Abeni D Pastore A Rizzo C Orzalesi M et al Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators Pediatr Nephrol 2001 1611862 7 10.1007/s00467010070211685590Open DOISearch in Google Scholar

36Dixon M, MacDonald A, White F, Stafford J. Disorders of amino acid metabolism, organic acidaemias and urea cycle disorders. p. 381–525. doi: 10.1002/9781118915349.ch17. In: Shaw V, editor. Clinical paediatric dietetics. 4th ed. Chichester, West Sussex: John Wiley & Sons Ltd.; 2015; 864 p. ISBN 978-0470659984. Online ISBN: 978-1118915349. doi: 10.1002/9781118915349. Dixon M MacDonald A White F Stafford J Disorders of amino acid metabolism, organic acidaemias and urea cycle disorders 381–525 10.1002/9781118915349.ch17 In: Shaw V, editor. Clinical paediatric dietetics. 4th ed. Chichester, West Sussex: John Wiley & Sons Ltd.; 2015; 864 p. ISBN 978-0470659984. Online ISBN: 978-1118915349 10.1002/9781118915349Open DOISearch in Google Scholar

37Burlina AB. Hepatocyte transplantation for inborn errors of metabolism. J Inherit Metab Dis. 2004;27(3):373–83. doi: 10.1023/B:BOLI.0000031095.57411.8d Burlina AB Hepatocyte transplantation for inborn errors of metabolism J Inherit Metab Dis 2004 273373 83 10.1023/B:BOLI.0000031095.57411.8dOpen DOISearch in Google Scholar

38Gallicano GI, Mishra L. Hepatocytes from induced pluripotent stem cells: a giant leap forward for hepatology. Hepatology. 2010;51(1):20–2. doi: 10.1002/hep.23474 Gallicano GI Mishra L Hepatocytes from induced pluripotent stem cells: a giant leap forward for hepatology Hepatology 2010 51120 2 10.1002/hep.23474382155520034034Open DOISearch in Google Scholar

39Puppi J, Tan N, Mitry RR, Hughes RD, Lehec S, Mieli-Vergani G, et al. Hepatocyte transplantation followed by auxiliary liver transplantation – a novel treatment for ornithine transcarbamylase deficiency. Am J Transplant. 2008;8(2):452–7. doi: 10.1111/j.1600-6143.2007.02058.x Puppi J Tan N Mitry RR Hughes RD Lehec S Mieli-Vergani G et al Hepatocyte transplantation followed by auxiliary liver transplantation – a novel treatment for ornithine transcarbamylase deficiency Am J Transplant 2008 82452 7 10.1111/j.1600-6143.2007.02058.x18211511Open DOISearch in Google Scholar

40Spada M, Porta F, Righi D, Gazzera C, Tandoi F, Ferrero I, et al. Intrahepatic administration of human liver stem cells in infants with inherited neonatal-onset hyperammonemia: a phase i study. Stem Cell Rev Rep. 2020;16(1):186–97. doi: 10.1007/s12015-019-09925-z Spada M Porta F Righi D Gazzera C Tandoi F Ferrero I et al Intrahepatic administration of human liver stem cells in infants with inherited neonatal-onset hyperammonemia: a phase i study Stem Cell Rev Rep 2020 161186 97 10.1007/s12015-019-09925-z698713431792768Open DOISearch in Google Scholar

41Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 2009;96(4):151–7. doi: 10.1016/j.ymgme.2008.12.016 Wilson JM Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency Mol Genet Metab 2009 964151 7 10.1016/j.ymgme.2008.12.01619211285Open DOISearch in Google Scholar

42Wang L, Bell P, Morizono H, He Z, Pumbo E, Yu H, et al. AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. Mol Genet Metab. 2017;120(4):299–305. doi: 10.1016/j.ymgme.2017.02.011 Wang L Bell P Morizono H He Z Pumbo E Yu H et al AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice Mol Genet Metab 2017 1204299 305 10.1016/j.ymgme.2017.02.011542326728283349Open DOISearch in Google Scholar

43Burrage LC, Sun Q, Elsea SH, Jiang MM, Nagamani SC, Frankel AE, et al. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. Hum Mol Genet. 2015;24(22):6417–27. doi: 10.1093/hmg/ddv352 Burrage LC Sun Q Elsea SH Jiang MM Nagamani SC Frankel AE et al Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency Hum Mol Genet 2015 24226417 27 10.1093/hmg/ddv352500760826358771Open DOISearch in Google Scholar